Hirokazu Nakayama

6PUBLICATIONS
0CO-AUTHORS
Predictive and prognostic markersMedical infection agents (incl. prions)HaematologyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 07, 2025
Impact of Substantial Weight Loss on Digoxin Intoxication During Long-term Therapy.

Hirokazu Nakayama, Tsuyoshi Shiga, Masayo Tanaka

|Apr 14, 2025
A preliminary retrospective study of the safety of Vancomycin area under the curve in patients treated with concomitant use of Vancomycin and gentamicin.

Hirokazu Nakayama, Yoshitsugu Nakamura, Masayo Tanaka

|May 31, 2023
Abrupt increased serum creatinine in a hyperferritinemia patient treated with deferoxamine after cord blood transplantation: a case report with literature review.

Hirokazu Nakayama, Yoshimasa Kamoda, Michiya Tanuma

|Jan 23, 2023
Is higher lymphocyte count a potential strategy for preventing chronic kidney disease in patients receiving long-term dasatinib treatment?

Hirokazu Nakayama, Hiromitsu Iizuka, Toshiaki Kato

|Jun 03, 2019
Vancomycin Pharmacokinetics in Patients with Advanced Cancer Near End of Life.

Hirokazu Nakayama, Masahiro Suzuki, Toshiaki Kato

|Jul 21, 2018
Reduced Clearance of Phenobarbital in Advanced Cancer Patients near the End of Life.

Hirokazu Nakayama, Hirotoshi Echizen, Ryuichi Ogawa

Pageof 1

Frequent Collaborators